HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ambrosino, E. Articles by Berzofsky, J. A. Search for Related Content PubMed PubMed Citation Articles by Ambrosino, E. Articles by Berzofsky, J. A.

Cross-Regulation between Type I and Type II NKT Cells in Regulating Tumor Immunity: A New Immunoregulatory Axis¹

Elena Ambrosino^*, Masaki Terabe^2,*, Ramesh C. Halder, Judy Peng^*, Shun Takaku^*, Sachiko Miyake, Takashi Yamamura, Vipin Kumar and Jay A. Berzofsky^*

^* National Cancer Institute, Bethesda, MD 20892; Torrey Pines Institute for Molecular Studies, San Diego, CA 92121; and National Institute of Neuroscience, Tokyo, Japan

Negative immunoregulation is a major barrier to successful cancer immunotherapy. The NKT cell is known to be one such regulator. In this study we explored the roles of and interaction between the classical type I NKT cell and the poorly understood type II NKT cell in the regulation of tumor immunity. Selective stimulation of type II NKT cells suppressed immunosurveillance, whereas stimulation of type I NKT cells protected against tumor growth even when responses were relatively skewed toward Th2 cytokines. When both were stimulated simultaneously, type II NKT cells appeared to suppress the activation in vitro and protective effect in vivo of type I NKT cells. In the absence of type I, suppression by type II NKT cells increased, suggesting that type I cells reduce the suppressive effect of type II NKT cells. Thus, in tumor immunity type I and type II NKT cells have opposite and counteractive roles and define a new immunoregulatory axis. Alteration of the balance between the protective type I and the suppressive type II NKT cell may be exploited for therapeutic intervention in cancer.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was partially supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, and Center for Cancer Research.

² Address correspondence and reprint requests to Dr. Masaki Terabe, Vaccine Branch, National Cancer Institute, Building 10, Room 6B-12, 10 Center Drive, National Institutes of Health, Bethesda, MD 20892. E-mail address: terabe{at}mail.nih.gov

³ Abbreviations used in this paper: GalCer, -galactosylceramide; WT, wild type.

This article has been cited by other articles:

				H. Wakao, R. Wakao, S. Sakata, K. Iwabuchi, A. Oda, and H. Fujita In vitro induction of natural killer T cells from embryonic stem cells prepared using somatic cell nuclear transfer FASEB J, July 1, 2008; 22(7): 2223 - 2231. [Abstract] [Full Text] [PDF]

				J. A. Berzofsky and M. Terabe NKT Cells in Tumor Immunity: Opposing Subsets Define a New Immunoregulatory Axis J. Immunol., March 15, 2008; 180(6): 3627 - 3635. [Abstract] [Full Text] [PDF]

				Y. Li, D. Zhou, C. Xia, P. G. Wang, and S. B. Levery Sensitive quantitation of isoglobotriaosylceramide in the presence of isobaric components using electrospray ionization-ion trap mass spectrometry Glycobiology, February 1, 2008; 18(2): 166 - 176. [Abstract] [Full Text] [PDF]